Who are Lapaquistat acetate and ezetimibe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atorvastatin, Ezetimibe, atorvastatin plus ezetimibe, Fixed combination simvastatin/ezetimibe, statins, ezetimibe, simvastatin and ezetimibe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lapaquistat-acetate-and-ezetimibe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lapaquistat acetate and ezetimibe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lapaquistat acetate and ezetimibe (Lapaquistat acetate and ezetimibe) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholesterol absorption inhibitor combination. Area: Cardiovascular.

phase 3 Cholesterol absorption inhibitor combination ACAT2 and NPC1L1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lapaquistat acetate and ezetimibe (Lapaquistat acetate and ezetimibe) — Takeda. Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lapaquistat acetate and ezetimibe TARGET	Lapaquistat acetate and ezetimibe	Takeda	phase 3	Cholesterol absorption inhibitor combination	ACAT2 and NPC1L1
Atorvastatin, Ezetimibe	Atorvastatin, Ezetimibe	Abant Izzet Baysal University	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
atorvastatin plus ezetimibe	atorvastatin plus ezetimibe	Shanghai Jiao Tong University School of Medicine	marketed	Statin plus cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
Fixed combination simvastatin/ezetimibe	Fixed combination simvastatin/ezetimibe	Novartis	marketed	Statin/cholesterol absorption inhibitor combination	HMG-CoA reductase (simvastatin); Niemann-Pick C1-like 1 protein (ezetimibe)
statins, ezetimibe	statins, ezetimibe	Korea University Anam Hospital	marketed	HMG-CoA reductase inhibitor and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
simvastatin and ezetimibe	simvastatin and ezetimibe	UMC Utrecht	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase and NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholesterol absorption inhibitor combination class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lapaquistat acetate and ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/lapaquistat-acetate-and-ezetimibe. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab